HL
HLNCF.US Haleon plc
- Market cap
- USD 40.0B
- P/E
- 19.0x
- P/B
- 1.84x
- ROE
- 10.1%
- Dividend yield
- 2.16%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is HLNCF.US undervalued?
Graham numberHLNCF.US trades 24.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Haleon plc fundamental analysis
No fundamental analysis for Haleon plc yet.
Haleon plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.…
Full company profileHaleon plc financial statements
Haleon plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 8.48B | 9.89B | 9.55B | 10.9B | 11.3B | 11.2B | 11.0B |
| Gross Profit | 4.80B | 5.91B | 5.95B | 6.58B | 6.96B | 6.82B | 7.14B |
| Operating Income | 897M | 1.60B | 1.64B | 1.83B | 2.00B | 2.21B | 2.58B |
| EBITDA | 1.17B | 1.91B | 2.21B | 2.18B | 2.35B | 2.63B | 2.94B |
| Net Income | 655M | 1.15B | 1.39B | 1.06B | 1.05B | 1.44B | 1.67B |
| EPS | 0.07 | 0.12 | 0.15 | 0.11 | 0.11 | 0.16 | 0.18 |
| Balance Sheet | |||||||
| Total Assets | 35.7B | 34.1B | 34.5B | 34.8B | 34.1B | 34.3B | 32.6B |
| Total Liabilities | 8.30B | 7.91B | 7.97B | 18.4B | 17.3B | 18.1B | 16.1B |
| Shareholders' Equity | 27.3B | 26.1B | 26.4B | 16.3B | 16.6B | 16.2B | 16.4B |
| Cash & Short-term Investments | 340M | 334M | 414M | 684M | 1.04B | 2.20B | 1.32B |
| Total Debt | 642M | 487M | 991M | 10.4B | 9.46B | 10.1B | 8.61B |
| Cash Flow | |||||||
| Operating Cash Flow | 786M | 1.41B | 1.36B | 2.06B | 2.10B | 2.30B | 2.34B |
| Capital Expenditure | 243M | 318M | 298M | 328M | 336M | 318M | 322M |
| Free Cash Flow | 543M | 1.09B | 1.06B | 1.74B | 1.76B | 1.98B | 2.01B |
| Ratios | |||||||
| ROE | 2.4% | 4.4% | 5.3% | 6.5% | 6.3% | 8.9% | 10.1% |
| ROA | 1.8% | 3.4% | 4.0% | 3.0% | 3.1% | 4.2% | 5.1% |
| Net Profit Margin | 7.7% | 11.6% | 14.6% | 9.8% | 9.3% | 12.8% | 15.1% |
| Debt to Equity | 0.02x | 0.02x | 0.04x | 0.64x | 0.57x | 0.62x | 0.52x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Haleon plc dividends
- Dividend yield
- 2.16%
- Forward dividend
- 0.10 USD
- Payout ratio
- 36.7%
- Ex-dividend date
- Aug 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 612M | 0.07 | 36.7% |
| 2024 | GBP 570M | 0.06 | 39.5% |
| 2023 | GBP 388M | 0.04 | 37.0% |
| 2022 | GBP 2.68B | 0.29 | 253.0% |
| 2021 | USD 1.15B | 0.12 | 82.6% |
| 2020 | USD 2.37B | 0.26 | 207.1% |
| 2019 | USD 1.15B | 0.12 | 175.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Haleon plc
- Insiders 0.22%
- Institutions 58.97%
- Public & others 40.81%
- Shares outstanding 8.78B
- Free float 8.86B
Haleon plc company profile
- Company name
- Haleon plc
- Ticker
- HLNCF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 24,535
- Fiscal year end
- December
- Address
- The Heights, Weybridge, United Kingdom, KT13 0NY
- Phone
- 44 1932 959 500
- Website
- haleon.com
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Haleon plc management
10- Mr. Brian James McNamaraCEO & Executive Director · born 1966
- Ms. Dawn Amanda AllenCFO & Director · born 1968
- Ms. Claire DicksonChief Digital & Technology Officer
- Ms. Joanne RussellHead of Investor Relations
- Mr. Adrian Charles MorrisGeneral Counsel · born 1967
- Ms. Tamara Jane RogersChief Marketing Officer · born 1968
- Ms. Line De DeckerChief Human Resources Officer · born 1974
- Mr. Filippo LanziPresident of EMEA & LatAm
- Mr. Keith ChoyPresident of Asia Pacific · born 1969
- Mr. Bjorn TimelinHead of Strategy